AI Article Synopsis

  • The neuraminidase inhibitor oseltamivir can lead to drug resistance in influenza viruses due to specific mutations in the neuraminidase protein.
  • An isolated strain from an immunocompromised patient showed up to a 350-fold increase in resistance to oseltamivir compared to a control virus.
  • Two new variants, E119V and E119I, were identified, with E119I also demonstrating reduced susceptibility to other antiviral drugs, highlighting the challenges of monitoring and treating multidrug-resistant influenza in patients.

Article Abstract

The clinical use of the neuraminidase inhibitor (NAI) oseltamivir is associated with the emergence of drug resistance resulting from subtype-specific neuraminidase (NA) mutations. The influenza A/Texas/12/2007 (H3N2) virus isolated from an oseltamivir-treated immunocompromised patient exhibited reduced susceptibility to oseltamivir in the chemiluminescent neuraminidase inhibition (NI) assay (approximately 60-fold increase in its 50% inhibitory concentration [IC(50)] compared to that for a control virus). When further propagated in cell culture, the isolate maintained reduced susceptibility to oseltamivir in both chemiluminescent and fluorescent NI assays (approximately 50- and 350-fold increases in IC(50), respectively). Sequencing analysis of the isolate revealed a mix of nucleotides coding for amino acids at position 119 of the NA [E119(V/I)]. Plaque purification of the isolate yielded E119V and E119I variants, both exhibiting reduced susceptibility to oseltamivir. The E119I variant also showed decreased susceptibility to zanamivir and the investigational NAIs peramivir and A-315675. The emergence of E119V variants in oseltamivir-treated patients has been previously reported; however, the E119I mutation detected here is a novel one which reduces susceptibility to several NAIs. Both mutations were not detected in unpropagated original clinical specimens using either conventional sequencing or pyrosequencing, suggesting that these variants were present in very low proportions (<10%) in clinical specimens and gained dominance after virus propagation in MDCK cells. All virus isolates recovered from the patient were resistant to adamantanes. Our findings highlight the potential for emergence and persistence of multidrug-resistant influenza viruses in oseltamivir-treated immunocompromised subjects and also highlight challenges for drug resistance diagnosis due to the genetic instability of the virus population upon propagation in cell culture.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2863645PMC
http://dx.doi.org/10.1128/AAC.01608-09DOI Listing

Publication Analysis

Top Keywords

reduced susceptibility
12
susceptibility oseltamivir
12
e119v e119i
8
mutations influenza
8
immunocompromised patient
8
oseltamivir chemiluminescent
8
oseltamivir
5
susceptibility
5
detection e119v
4
e119i
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!